Previous close | 155.30 |
Open | 155.28 |
Bid | 157.50 x 800 |
Ask | 158.24 x 800 |
Day's range | 154.59 - 158.48 |
52-week range | 134.09 - 175.91 |
Volume | |
Avg. volume | 6,384,056 |
Market cap | 278.769B |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | 23.41 |
EPS (TTM) | 6.75 |
Earnings date | 27 Apr 2023 - 01 May 2023 |
Forward dividend & yield | 5.92 (3.81%) |
Ex-dividend date | 13 Apr 2023 |
1y target est | 163.87 |
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.